{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T13:02:15Z","timestamp":1776949335221,"version":"3.51.4"},"reference-count":57,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives:<\/jats:title>\n                    <jats:p>Despite a good response to first-line chemotherapy, small-cell lung cancer (SCLC) has high relapse rates and a poor prognosis. We conducted a systematic review and meta-analysis to assess the role of immune checkpoint inhibitors (ICIs) in the treatment of extended stage SCLC (ES-SCLC), in different lines of therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Medline (PubMed), EMBASE, and Cochrane Library databases between January 2010 and March 2025 and conference proceedings between 2018 and 2025 were searched for RCTs assessing ICIs versus chemotherapy in patients with ES-SCLC. Primary endpoints were overall survival (OS) and progression-free survival (PFS). Secondary endpoints included objective response rate (ORR) and grade 3+ adverse events. Pooled hazard ratios (HR) for OS and PFS were meta-analyzed using the generic inverse variance method, and random-effect models were used to compute pooled estimates. Subgroup analyses compared survival by line of therapy, sex, age, and ECOG status.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>ICIs decreased risk of death by 19% (HR: 0.81, 95% CI: 0.76-0.86). OS benefit was regardless of age, sex, or ECOG, but only in first-line treatment. ICIs decreased the risk of disease progression by 22% (HR: 0.78, 95% CI: 0.67-0.91), with PFS benefit restricted to first-line treatment with a detrimental effect in the second line. ICIs improved ORR (OR: 0.79, 95% CI: 0.66-0.95), but were associated with increased grade 3+diarrhea (OR: 3.63, 95% CI: 1.46-9.02).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>ICIs conferred efficacy benefits and an acceptable safety profile in the treatment of patients with ES-SCLC in the first-line, but should not be used in the second-line as single agents. Biomarkers predicting long-term benefit are needed to further improve outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/coc.0000000000001265","type":"journal-article","created":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T18:01:48Z","timestamp":1765303308000},"page":"219-228","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Immunotherapy in Extensive Stage Small-Cell Lung Cancer in First-Line and Second-Line Setting"],"prefix":"10.1097","volume":"49","author":[{"given":"Nupur","family":"Krishnan","sequence":"first","affiliation":[{"name":"Global Health, Michael G. DeGroote School of Medicine, McMaster University, Hamilton"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patsy","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Schulich School of Medicine and Dentistry, Western University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriel","family":"Boldt","sequence":"additional","affiliation":[{"name":"Department of Oncology, London Health Sciences Centre"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suganija","family":"Lakkunarajah","sequence":"additional","affiliation":[{"name":"BC Cancer Agency, University of British Columbia, Vancouver, BC"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saurav","family":"Verma","sequence":"additional","affiliation":[{"name":"Department of Oncology, Division of Medical Oncology, Verspeeten Family Cancer Centre, London Health Sciences Centre and Western University, London, ON"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Phillip","family":"Blanchette","sequence":"additional","affiliation":[{"name":"Department of Oncology, Division of Medical Oncology, Verspeeten Family Cancer Centre, London Health Sciences Centre and Western University, London, ON"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacques","family":"Raphael","sequence":"additional","affiliation":[{"name":"Department of Oncology, Division of Medical Oncology, Verspeeten Family Cancer Centre, London Health Sciences Centre and Western University, London, ON"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2025,12,9]]},"reference":[{"key":"R1-20260423","first-page":"209","article-title":"Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"R2-20260423","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1093\/jnci\/83.12.855","article-title":"Randomized trial of cyclophosphamide, doxorubicin, and vincristine versus cisplatin and etoposide versus alternation of these regimens in small-cell lung cancer","volume":"83","author":"Fukuoka","year":"1991","journal-title":"J Natl Cancer Inst"},{"key":"R3-20260423","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1200\/JCO.1992.10.2.282","article-title":"Randomized study of cyclophosphamide, doxorubicin, and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive small-cell lung cancer: a phase III trial of the Southeastern Cancer Study Group","volume":"10","author":"Roth","year":"1992","journal-title":"J Clin Oncol"},{"key":"R4-20260423","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1056\/NEJMoa1809064","article-title":"First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer","volume":"379","author":"Horn","year":"2018","journal-title":"N Engl J Med"},{"key":"R5-20260423","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1016\/S0140-6736(19)32222-6","article-title":"Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial","volume":"394","author":"Paz-Ares","year":"2019","journal-title":"Lancet"},{"key":"R6-20260423","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1038\/ng.2396","article-title":"Integrative genome analyses identify key somatic driver mutations of smallcell lung cancer","volume":"44","author":"Peifer","year":"2012","journal-title":"Nat Genet"},{"key":"R7-20260423","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1200\/JCO.2017.75.3384","article-title":"Molecular determinants of response to anti-programmed cell death (PD)-1 and antiprogrammed death-ligand 1 (PD-L1) blockade in patients with non-small-cell lung cancer profiled with targeted next-generation sequencing","volume":"36","author":"Rizvi","year":"2018","journal-title":"J Clin Oncol"},{"key":"R8-20260423","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1089\/107999099314180","article-title":"Concomitant chemotherapy and IFN-alpha for small cell lung cancer: a randomized multicenter phase III study","volume":"19","author":"Ruotsalainen","year":"1999","journal-title":"J Interferon Cytokine Res"},{"key":"R9-20260423","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1517\/14712598.2010.484801","article-title":"INGN-225: a dendritic cell-based p53 vaccine (Ad.p53-DC) in small cell lung cancer: observed association between immune response and enhanced chemotherapy effect","volume":"10","author":"Chiappori","year":"2010","journal-title":"Expert Opin Biol Ther"},{"key":"R10-20260423","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1158\/1078-0432.CCR-05-2013","article-title":"Combination of p53 cancer vaccine with chemotherapy in patients with extensivestage small-cell lung cancer","volume":"12","author":"Antonia","year":"2006","journal-title":"Clin Cancer Res"},{"key":"R11-20260423","doi-asserted-by":"crossref","first-page":"9000","DOI":"10.1200\/JCO.2020.38.15_suppl.9000","article-title":"Randomized phase II clinical trial of cisplatin\/carboplatin and etoposide (CE) alone or in combination with nivolumab as frontline therapy for extensivestage small cell lung cancer (ES-SCLC): ECOG-ACRIN EA5161","volume":"38","author":"Leal","year":"2020","journal-title":"J Clin Oncol"},{"key":"R12-20260423","doi-asserted-by":"crossref","first-page":"2369","DOI":"10.1200\/JCO.20.00793","article-title":"Pembrolizumab or placebo plus etoposide and platinum as first-line therapy for extensive-stage small-cell lung cancer: randomized, doubleblind, phase III KEYNOTE-604 study","volume":"38","author":"Rudin","year":"2020","journal-title":"J Clin Oncol"},{"key":"R13-20260423","doi-asserted-by":"crossref","first-page":"8505","DOI":"10.1200\/JCO.2022.40.16_suppl.8505","article-title":"Serplulimab, a novel anti-PD-1 antibody, plus chemotherapy versus chemotherapy alone as first-line treatment for extensive-stage small-cell lung cancer: an international randomized phase 3 study","volume":"40","author":"Cheng","year":"2022","journal-title":"J Clin Oncol"},{"key":"R14-20260423","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/S1470-2045(22)00224-8","article-title":"Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensivestage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"23","author":"Wang","year":"2022","journal-title":"Lancet Oncol"},{"key":"R15-20260423","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1016\/j.jtho.2024.03.008","article-title":"Tislelizumab plus platinum and etoposide versus placebo plus platinum and etoposide as firstline treatment for extensive-stage SCLC (RATIONALE-312): a multicenter, double-blind, placebo-controlled, randomized, phase 3 clinical trial","volume":"19","author":"Cheng","year":"2024","journal-title":"J Thorac Oncol"},{"key":"R16-20260423","doi-asserted-by":"crossref","first-page":"9046","DOI":"10.3390\/curroncol29120709","article-title":"Chemoimmunotherapy in first line extensive stage small cell lung cancer (ES-SCLC): a systematic review and meta-analysis","volume":"29","author":"Sathiyapalan","year":"2022","journal-title":"Curr Oncol"},{"key":"R17-20260423","doi-asserted-by":"crossref","first-page":"e2015748","DOI":"10.1001\/jamanetworkopen.2020.15748","article-title":"Comparison of first-line treatments for patients with extensive-stage small cell lung cancer: a systematic review and network meta-analysis","volume":"3","author":"Zhou","year":"2020","journal-title":"JAMA Netw Open"},{"key":"R18-20260423","doi-asserted-by":"crossref","first-page":"1197044","DOI":"10.3389\/fimmu.2023.1197044","article-title":"Efficacy and safety of first-line immunotherapy plus chemotherapy in treating patients with extensive-stage small cell lung cancer: a Bayesian network meta-analysis","volume":"14","author":"Zhang","year":"2023","journal-title":"Front Immunol"},{"key":"R19-20260423","doi-asserted-by":"crossref","first-page":"e70256","DOI":"10.1002\/cam4.70256","article-title":"The optimal first-line therapy for extensive-stage small-cell lung cancer based on liver metastasis status: a network meta-analysis and systematic review","volume":"13","author":"Zhang","year":"2024","journal-title":"Cancer Med"},{"key":"R20-20260423","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"Brit Med J"},{"key":"R21-20260423","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"R22-20260423","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"Brit Med J"},{"key":"R23-20260423","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1136\/bmj.328.7454.1490","article-title":"Grading quality of evidence and strength of recommendations","volume":"328","author":"Atkins","year":"2004","journal-title":"Brit Med J"},{"key":"R24-20260423","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1002\/9781119536604.ch10","article-title":"Group obotCSM. Analysing data and undertaking meta-analyses","author":"Deeks","year":"2019","journal-title":"Cochrane Handbook System Rev Interv"},{"key":"R25-20260423","doi-asserted-by":"crossref","first-page":"3740","DOI":"10.1200\/JCO.2016.67.6601","article-title":"Phase III Randomized Trial of Ipilimumab Plus Etoposide and Platinum Versus Placebo Plus Etoposide and Platinum in Extensive-Stage Small-Cell Lung Cancer","volume":"34","author":"Reck","year":"2016","journal-title":"J Clin Oncol"},{"key":"R26-20260423","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S1470-2045(20)30539-8","article-title":"Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial","volume":"22","author":"Goldman","year":"2021","journal-title":"Lancet Oncol"},{"key":"R27-20260423","doi-asserted-by":"crossref","first-page":"114372","DOI":"10.1016\/j.intimp.2025.114372","article-title":"The efficacy of ICIs rechallenge in advanced small cell lung cancer after progression from ICIs plus chemotherapy: A real-world study","volume":"152","author":"Liu","year":"2025","journal-title":"Int Immunopharmacol"},{"key":"R28-20260423","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1200\/JCO.20.02212","article-title":"Nivolumab and Ipilimumab as Maintenance Therapy in Extensive-Disease Small-Cell Lung Cancer: CheckMate 451","volume":"39","author":"Owonikoko","year":"2021","journal-title":"J Clin Oncol"},{"key":"R29-20260423","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/j.jtho.2019.01.008","article-title":"A randomized non-comparative phase ii study of anti-programmed cell deathligand 1 atezolizumab or chemotherapy as second-line therapy in patients with small cell lung cancer: results from the IFCT- 1603 trial","volume":"14","author":"Pujol","year":"2019","journal-title":"J Thorac Oncol"},{"key":"R30-20260423","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.annonc.2021.01.071","article-title":"Second-line nivolumab in relapsed small-cell lung cancer: CheckMate 331 (\u2606)","volume":"32","author":"Spigel","year":"2021","journal-title":"Ann Oncol"},{"key":"R31-20260423","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.21037\/apm-20-449","article-title":"Comparison between the first-line and second-line immunotherapy drugs in the progression-free survival and overall survival in advanced non-small cell lung cancer: a systematic review and meta-analysis of randomized controlled trials","volume":"10","author":"Wu","year":"2021","journal-title":"Ann Palliat Med"},{"key":"R32-20260423","doi-asserted-by":"crossref","first-page":"v462","DOI":"10.1093\/annonc\/mdz252.030","article-title":"First line versus second line immunotherapy in recurrent\/metastatic squamous cell carcinoma of the head and neck","volume":"30","author":"Even","year":"2019","journal-title":"Ann Oncol"},{"key":"R33-20260423","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1007\/s00432-021-03858-2","article-title":"Safety and efficacy of ICI plus anlotinib vs. anlotinib alone as third-line treatment in extensivestage small cell lung cancer: a retrospective study","volume":"148","author":"Chen","year":"2022","journal-title":"J Cancer Res Clin Oncol"},{"key":"R34-20260423","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1186\/s12967-019-1847-x","article-title":"A nomogram to predict survival in non-small cell lung cancer patients treated with nivolumab","volume":"17","author":"Botticelli","year":"2019","journal-title":"J Transl Med"},{"key":"R35-20260423","doi-asserted-by":"crossref","first-page":"4915","DOI":"10.1158\/1078-0432.CCR-18-1311","article-title":"Bigger is not always better: tumor size and prognosis in advanced melanoma","volume":"24","author":"Warner","year":"2018","journal-title":"Clin Cancer Res"},{"key":"R36-20260423","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1016\/j.rmed.2010.07.013","article-title":"Lactate dehydrogenase as prognostic factor in limited and extensive disease stage small cell lung cancer - a retrospective single institution analysis","volume":"104","author":"Hermes","year":"2010","journal-title":"Respir Med"},{"key":"R37-20260423","doi-asserted-by":"crossref","first-page":"617","DOI":"10.3892\/ol.2012.792","article-title":"Specific organ metastases and survival in small cell lung cancer","volume":"4","author":"Nakazawa","year":"2012","journal-title":"Oncol Lett"},{"key":"R38-20260423","doi-asserted-by":"crossref","first-page":"53245","DOI":"10.18632\/oncotarget.10644","article-title":"Prognostic effect of liver metastasis in lung cancer patients with distant metastasis","volume":"7","author":"Ren","year":"2016","journal-title":"Oncotarget"},{"key":"R39-20260423","doi-asserted-by":"crossref","first-page":"1230824","DOI":"10.3389\/fphar.2023.1230824","article-title":"Drug resistance mechanism and reversal strategy in lung cancer immunotherapy","volume":"14","author":"Xu","year":"2023","journal-title":"Front Pharmacol"},{"key":"R40-20260423","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1200\/JCO.21.01845","article-title":"Managing resistance to immune checkpoint inhibitors in lung cancer: treatment and novel strategies","volume":"40","author":"Passaro","year":"2022","journal-title":"J Clin Oncol"},{"key":"R41-20260423","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1016\/j.annonc.2021.08.2151","article-title":"Clinical definition of acquired resistance to immunotherapy in patients with metastatic non-small-cell lung cancer","volume":"32","author":"Schoenfeld","year":"2021","journal-title":"Ann Oncol"},{"key":"R42-20260423","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.ccell.2020.03.017","article-title":"Acquired resistance to immune checkpoint inhibitors","volume":"37","author":"Schoenfeld","year":"2020","journal-title":"Cancer Cell"},{"key":"R43-20260423","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s40425-018-0336-8","article-title":"Efficacy of PD-1 & PD-L1 inhibitors in older adults: a meta-analysis","volume":"6","author":"Elias","year":"2018","journal-title":"J Immunother Cancer"},{"key":"R44-20260423","doi-asserted-by":"crossref","first-page":"5347","DOI":"10.1158\/1078-0432.CCR-18-1116","article-title":"Age correlates with response to anti-PD1, reflecting age-related differences in intratumoral effector and regulatory T-cell populations","volume":"24","author":"Kugel","year":"2018","journal-title":"Clin Cancer Res"},{"key":"R45-20260423","first-page":"e1568810","article-title":"Correlation between patients\u2019 age and cancer immunotherapy efficacy","volume":"8","author":"Wu","year":"2019","journal-title":"Oncoimmunology"},{"key":"R46-20260423","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1002\/aac2.12045","article-title":"Immune checkpoint expression and relationships to anti-PD-L1 immune checkpoint blockade cancer immunotherapy efficacy in aged versus young mice","volume":"3","author":"Garcia","year":"2022","journal-title":"Aging Cancer"},{"key":"R47-20260423","doi-asserted-by":"crossref","first-page":"786046","DOI":"10.3389\/fimmu.2021.786046","article-title":"Impact of patient age on clinical efficacy and toxicity of checkpoint inhibitor therapy","volume":"12","author":"Wong","year":"2021","journal-title":"Front Immunol"},{"key":"R48-20260423","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1002\/ijc.31301","article-title":"Correlation between sex and efficacy of immune checkpoint inhibitors (PD-1 and CTLA-4 inhibitors)","volume":"143","author":"Wu","year":"2018","journal-title":"Int J Cancer"},{"key":"R49-20260423","doi-asserted-by":"crossref","first-page":"542","DOI":"10.3390\/jcm7120542","article-title":"Effect of gender on the outcome of patients receiving immune checkpoint inhibitors for advanced cancer: a systematic review and meta-analysis of phase III randomized clinical trials","volume":"7","author":"Grassadonia","year":"2018","journal-title":"J Clin Med"},{"key":"R50-20260423","doi-asserted-by":"crossref","first-page":"1024112","DOI":"10.3389\/fimmu.2022.1024112","article-title":"Sex \u2014 a potential factor affecting immune checkpoint inhibitor therapy for cancers","volume":"13","author":"Hu","year":"2022","journal-title":"Front Immunol"},{"key":"R51-20260423","doi-asserted-by":"crossref","first-page":"3214","DOI":"10.3390\/molecules24183214","article-title":"Sex differences in cancer immunotherapy efficacy, biomarkers, and therapeutic strategy","volume":"24","author":"Wang","year":"2019","journal-title":"Molecules"},{"key":"R52-20260423","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s13293-022-00469-5","article-title":"Advances in sex disparities for cancer immunotherapy: unveiling the dilemma of Yin and Yang","volume":"13","author":"Ma","year":"2022","journal-title":"Biol Sex Differ"},{"key":"R53-20260423","doi-asserted-by":"crossref","first-page":"941254","DOI":"10.3389\/fimmu.2022.941254","article-title":"Editorial: differential efficacy of immune checkpoint inhibitors due to age and sex factors","volume":"13","author":"Chong","year":"2022","journal-title":"Front Immunol"},{"key":"R54-20260423","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.3390\/biomedicines11071982","article-title":"Small cell lung carcinoma: current diagnosis, biomarkers, and treatment options with future perspectives","volume":"11","author":"Krpina","year":"2023","journal-title":"Biomedicines"},{"key":"R55-20260423","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.ccell.2020.12.014","article-title":"Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities","volume":"39","author":"Gay","year":"2021","journal-title":"Cancer Cell"},{"key":"R56-20260423","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.jtho.2021.08.763","article-title":"Molecular subtypes of primary SCLC tumors and their associations with neuroendocrine and therapeutic markers","volume":"17","author":"Qu","year":"2022","journal-title":"J Thorac Oncol"},{"key":"R57-20260423","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1038\/s41591-024-03398-5","article-title":"Prediction of checkpoint inhibitor immunotherapy efficacy for cancer using routine blood tests and clinical data","volume":"31","author":"Yoo","year":"2025","journal-title":"Nat Med"}],"container-title":["American Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/COC.0000000000001265","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T12:12:07Z","timestamp":1776946327000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/COC.0000000000001265"}},"subtitle":["A Systematic Review and Meta-Analysis"],"short-title":[],"issued":{"date-parts":[[2025,12,9]]},"references-count":57,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/coc.0000000000001265","relation":{},"ISSN":["0277-3732","1537-453X"],"issn-type":[{"value":"0277-3732","type":"print"},{"value":"1537-453X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,9]]}}}